{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:23:58Z","timestamp":1792153438284,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100009399","name":"Peking University Third Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04917-x","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:06:09Z","timestamp":1776848769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Obinutuzumab alone may be an effective option for adult minimal change disease: a single-center retrospective observational study"],"prefix":"10.1186","volume":"27","author":[{"given":"Qiong","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li Yuan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danxia","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"2","key":"4917_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2215\/CJN.05000516","volume":"12","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal Change Disease. Clin J Am Soc Nephrol. 2017;12(2):332\u201345. https:\/\/doi.org\/10.2215\/CJN.05000516.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"4917_CR2","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2215\/CJN.03531006","volume":"2","author":"M Waldman","year":"2007","unstructured":"Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2(3):445\u201353. https:\/\/doi.org\/10.2215\/CJN.03531006.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"4917_CR3","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.2215\/CJN.01920218","volume":"13","author":"JA Jefferson","year":"2018","unstructured":"Jefferson JA. Complications of Immunosuppression in Glomerular Disease. Clin J Am Soc Nephrol. 2018;13(8):1264\u201375. https:\/\/doi.org\/10.2215\/CJN.01920218.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"4917_CR4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s40265-023-01855-y","volume":"83","author":"L Deng","year":"2023","unstructured":"Deng L, Xu G. Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy. Drugs. 2023;83(6):507\u201330. https:\/\/doi.org\/10.1007\/s40265-023-01855-y.","journal-title":"Drugs"},{"issue":"3","key":"4917_CR5","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/ki.2012.444","volume":"83","author":"H Munyentwali","year":"2013","unstructured":"Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int. 2013;83(3):511\u20136. https:\/\/doi.org\/10.1038\/ki.2012.444.","journal-title":"Kidney Int"},{"issue":"10","key":"4917_CR6","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/ndt\/gfaa133","volume":"36","author":"C Heybeli","year":"2021","unstructured":"Heybeli C, Erickson SB, Fervenza FC, Hogan MC, Zand L, Leung N. Comparison of treatment options in adults with frequently relapsing or steroid-dependent minimal change disease. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association -. Eur Ren Association. 2021;36(10):1821\u20137. https:\/\/doi.org\/10.1093\/ndt\/gfaa133.","journal-title":"Eur Ren Association"},{"issue":"1","key":"4917_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.15232","volume":"182","author":"CL Freeman","year":"2018","unstructured":"Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol. 2018;182(1):29\u201345. https:\/\/doi.org\/10.1111\/bjh.15232.","journal-title":"Br J Haematol"},{"issue":"8","key":"4917_CR8","doi-asserted-by":"publisher","first-page":"100853","DOI":"10.1016\/j.xkme.2024.100853","volume":"6","author":"Y Lin","year":"2024","unstructured":"Lin Y, Han Q, Chen L, Wang Y, Ren P, Liu G, et al. Obinutuzumab in Refractory Membranous Nephropathy: A Case Series. Kidney Med. 2024;6(8):100853. https:\/\/doi.org\/10.1016\/j.xkme.2024.100853.","journal-title":"Kidney Med"},{"issue":"1","key":"4917_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12882-022-02761-3","volume":"23","author":"R Hudson","year":"2022","unstructured":"Hudson R, Rawlings C, Mon SY, Jefferis J, John GT. Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases. BMC Nephrol. 2022;23(1):134. https:\/\/doi.org\/10.1186\/s12882-022-02761-3.","journal-title":"BMC Nephrol"},{"issue":"8","key":"4917_CR10","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1016\/j.ekir.2024.05.004","volume":"9","author":"X Su","year":"2024","unstructured":"Su X, Wu B, Tie X, Guo X, Feng R, Qiao X, et al. Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy. Kidney Int Rep. 2024;9(8):2386\u201398. https:\/\/doi.org\/10.1016\/j.ekir.2024.05.004.","journal-title":"Kidney Int Rep"},{"issue":"9","key":"4917_CR11","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.ekir.2020.06.030","volume":"5","author":"S Sethi","year":"2020","unstructured":"Sethi S, Kumar S, Lim K, Jordan SC. Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy. Kidney Int Rep. 2020;5(9):1515\u20138. https:\/\/doi.org\/10.1016\/j.ekir.2020.06.030.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"4917_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","volume":"76","author":"N Klomjit","year":"2020","unstructured":"Klomjit N, Fervenza FC, Zand L. Successful Treatment of Patients With Refractory PLA(2)R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases. Am J Kidney Dis. 2020;76(6):883\u20138. https:\/\/doi.org\/10.1053\/j.ajkd.2020.02.444.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"4917_CR13","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/ndt\/gfae230","volume":"40","author":"M Xu","year":"2025","unstructured":"Xu M, Wang Y, Wu M, Chen R, Zhao W, Li M, et al. Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association -. Eur Ren Association. 2025;40(5):978\u201386. https:\/\/doi.org\/10.1093\/ndt\/gfae230.","journal-title":"Eur Ren Association"},{"issue":"4","key":"4917_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):753\u201379. https:\/\/doi.org\/10.1016\/j.kint.2021.05.015.","journal-title":"Kidney Int"},{"issue":"5","key":"4917_CR15","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1053\/j.ajkd.2016.10.032","volume":"69","author":"RJ Maas","year":"2017","unstructured":"Maas RJ, Deegens JK, Beukhof JR, Reichert LJ, Ten Dam MA, Beutler JJ, et al. The Clinical Course of Minimal Change Nephrotic Syndrome With Onset in Adulthood or Late Adolescence: A Case Series. Am J Kidney Dis. 2017;69(5):637\u201346. https:\/\/doi.org\/10.1053\/j.ajkd.2016.10.032.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"4917_CR16","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ekir.2023.02.1070","volume":"8","author":"N Guan","year":"2023","unstructured":"Guan N, Zhang M, Zhang M, Chen R, Xie Q, Hao CM. Rituximab as Initial Therapy in Adult Patients With Minimal Change Disease. Kidney Int Rep. 2023;8(5):1102\u20134. https:\/\/doi.org\/10.1016\/j.ekir.2023.02.1070.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"4917_CR17","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1681\/ASN.0000000520","volume":"36","author":"P Gauckler","year":"2025","unstructured":"Gauckler P, Matyjek A, Kapsia S, Marinaki S, Quintana LF, Diaz MM, et al. Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies. J Am Soc Nephrol. 2025;36(4):668\u201378. https:\/\/doi.org\/10.1681\/ASN.0000000520.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"4917_CR18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1681\/ASN.2012070734","volume":"24","author":"J Hogan","year":"2013","unstructured":"Hogan J, Radhakrishnan J. The treatment of minimal change disease in adults. J Am Soc Nephrol. 2013;24(5):702\u201311. https:\/\/doi.org\/10.1681\/ASN.2012070734.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"4917_CR19","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa2314471","volume":"391","author":"FE Hengel","year":"2024","unstructured":"Hengel FE, Dehde S, Lasse M, Zahner G, Seifert L, Schnarre A, et al. Autoantibodies Targeting Nephrin in Podocytopathies. N Engl J Med. 2024;391(5):422\u201333. https:\/\/doi.org\/10.1056\/NEJMoa2314471.","journal-title":"N Engl J Med"},{"key":"4917_CR20","doi-asserted-by":"publisher","unstructured":"Lin Y, Pan Y, Han Q, Xu J, Wang J, Lei X, et al. Obinutuzumab may be an effective and safe option for adult minimal change disease and focal segmental glomerulosclerosis patients after multitarget therapy including rituximab. Am J Nephrol. 2024;1\u201310. https:\/\/doi.org\/10.1159\/000541972.","DOI":"10.1159\/000541972"},{"issue":"8","key":"4917_CR21","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/ndt\/gfae061","volume":"39","author":"L Jin","year":"2024","unstructured":"Jin L, Liu X, Li H, Dang X, Wang Z, Niu D, et al. Obinutuzumab is effective for the treatment of frequently-relapsing\/steroid-dependent minimal change disease in adults. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association -. Eur Ren Association. 2024;39(8):1364\u20137. https:\/\/doi.org\/10.1093\/ndt\/gfae061.","journal-title":"Eur Ren Association"},{"issue":"12","key":"4917_CR22","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/nep.13554","volume":"24","author":"R Ramachandran","year":"2019","unstructured":"Ramachandran R, Bharati J, Rao I, Kashif AW, Nada R, Minz R, et al. Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy. Nephrol (Carlton Vic). 2019;24(12):1241\u20137. https:\/\/doi.org\/10.1111\/nep.13554.","journal-title":"Nephrol (Carlton Vic)"},{"issue":"4","key":"4917_CR23","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.ekir.2021.01.022","volume":"6","author":"M Teisseyre","year":"2021","unstructured":"Teisseyre M, Boyer-Suavet S, Cremoni M, Brglez V, Esnault V, Seitz-Polski B. Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy. Kidney Int Rep. 2021;6(4):1183\u20138. https:\/\/doi.org\/10.1016\/j.ekir.2021.01.022.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"4917_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1681\/ASN.2021060794","volume":"33","author":"AJB Watts","year":"2022","unstructured":"Watts AJB, Keller KH, Lerner G, Rosales I, Collins AB, Sekulic M, et al. Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology. J Am Soc Nephrol. 2022;33(1):238\u201352. https:\/\/doi.org\/10.1681\/ASN.2021060794.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"4917_CR25","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41581-024-00843-z","volume":"20","author":"K Meliambro","year":"2024","unstructured":"Meliambro K, He JC, Campbell KN. Podocyte-targeted therapies - progress and future directions. Nat Rev Nephrol. 2024;20(10):643\u201358. https:\/\/doi.org\/10.1038\/s41581-024-00843-z.","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"4917_CR26","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.2215\/CJN.0000000000000555","volume":"19","author":"X Hu","year":"2024","unstructured":"Hu X, Zhang M, Xu J, Gao C, Yu X, Li X, et al. Comparison of Obinutuzumab and Rituximab for Treating Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2024;19(12):1594\u2013602. https:\/\/doi.org\/10.2215\/CJN.0000000000000555.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"4917_CR27","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.ekir.2024.12.012","volume":"10","author":"M Teisseyre","year":"2025","unstructured":"Teisseyre M, Allinovi M, Audard V, Cremoni M, Belvederi G, Karame A, et al. Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies. Kidney Int Rep. 2025;10(3):753\u201361. https:\/\/doi.org\/10.1016\/j.ekir.2024.12.012.","journal-title":"Kidney Int Rep"},{"issue":"12","key":"4917_CR28","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2215\/CJN.0000000000000288","volume":"18","author":"C Dossier","year":"2023","unstructured":"Dossier C, Bonneric S, Baudouin V, Kwon T, Prim B, Cambier A, et al. Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children. Clin J Am Soc Nephrol. 2023;18(12):1555\u201362. https:\/\/doi.org\/10.2215\/CJN.0000000000000288.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4917_CR29","doi-asserted-by":"publisher","first-page":"1407461","DOI":"10.3389\/fimmu.2024.1407461","volume":"15","author":"Q Wang","year":"2024","unstructured":"Wang Q, Lin L, Zhen J, Jiang B, Liu G. Case report: Effective treatment of rituximab-resistant minimal change disease with obinutuzumab in an adult. Front Immunol. 2024;15:1407461. https:\/\/doi.org\/10.3389\/fimmu.2024.1407461.","journal-title":"Front Immunol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04917-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04917-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04917-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:13:53Z","timestamp":1780877633000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04917-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4917"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04917-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted ethically in accordance with the World Medical Association Declaration of Helsinki. The protocol has been approved by the Peking University Third Hospital Medical Science Research Ethics Committee (M2019218), and written informed consent from all the participants was obtained for the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"355"}}